PDCD1 and neoplasm: The antitumor activity of the anti-PD-1 antibody was significantly enhanced by the combination with the two drugs, which resulted in a reduced number of intratumoral myeloid-derived suppressor cells (MDSCs), likely associated with the chemotherapy-induced inhibition of Vascular Endothelial Growth Factor (VEGF) expression and tumor-associated blood vessels formation.